BLA 761376 · Dr Reddys Labs SA
Zimrixby
Rituximab-Cdxx
OrphanLast checked: Nov 20, 2026Latest source record: Jul 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 31, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,564
526 Phase 3, 340 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 31, 2026 Original approval OrphanLetterLabelMedication Guide
2 products under this application
- ZIMRIXBY · RITUXIMAB-CDXX 100MG/10ML · INJECTION, · Prescription
- ZIMRIXBY · RITUXIMAB-CDXX 500MG/50ML · INJECTION, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rituximab" as an intervention, any sponsor and status, largest first.
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesPivotal-lookingActive, not recruiting
University of Sao Paulo General HospitalAcademic, hospital or other
NCT05879419 · 2,005 participants (planned) · Start May 23, 2023 · Primary completion Dec 1, 2025
Drug: Recombinant Herpes Zoster Vaccine (RZV) · For: Rheumatoid Arthritis; Spondylitis, Ankylosing; Spondyloarthritis and 8 more
Sites: São Paulo, Brazil
- Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaPivotal-lookingCompleted
German High-Grade Non-Hodgkin's Lymphoma Study GroupAcademic, hospital or other
NCT00052936 · 1,506 participants · Start Jan 2001 · Primary completion Aug 5, 2010
Drug: filgrastim; rituximab and 5 more · For: Lymphoma
Sites: Aachen, Germany; Amberg, Germany; Ansbach, Germany · 174 sites in all
- HD18 for Advanced Stages in Hodgkins LymphomaPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT00515554 · 1,500 participants · Start May 2008 · Primary completion Jul 2019
Drug: Rituximab; BEACOPP escalated · For: Hodgkins Lymphoma
Sites: Cologne, Germany
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01287741 · 1,418 participants · Start Jul 26, 2011 · Primary completion Apr 29, 2016
Drug: Rituximab; Obinutuzumab and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 235 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01332968 · 1,401 participants · Start Jul 6, 2011 · Primary completion Feb 1, 2016
Drug: Obinutuzumab; Cyclophosphamide and 5 more · For: Non-Hodgkin's Lymphoma
Sites: Springdale, Arkansas; Irvine, California; Post Falls, Idaho · 183 sites in all
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasPivotal-lookingStatus unknown
Jurgen BarthAcademic, hospital or other
NCT00877214 · 1,272 participants · Start Apr 1, 2009 · Primary completion Dec 2024
Drug: Rituximab; Rituximab / observation · For: Follicular Lymphomas; Immunocytomas; Marginal Zone Lymphomas and 3 more
Sites: Giessen, Germany
- Primary Rituximab and MaintenancePivotal-lookingCompleted
Lymphoma Study AssociationAcademic, hospital or other
NCT00140582 · 1,217 participants · Start Dec 2004 · Primary completion May 2007
Drug: Rituximab · For: Follicular Lymphoma
Sites: Buenos Aires, Argentina; Melbourne, Australia; Ghent, Belgium · 24 sites in all
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, et al. · J Clin Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial.
Isaka Y, Sakaguchi Y, Shinzawa M, et al. · JAMA 2025 · Randomized Controlled Trial, Multicenter Study
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, et al. · N Engl J Med 2010 · Multicenter Study, Randomized Controlled Trial
Sponsor: Dr Reddys Labs SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.